Exploring the Clinical Efficacy of Qi Jiao Jiao Intervention in Mild to Moderate Ulcerative Colitis Patients Based on the Theory of "Spleen as the Guard"

注册号:

Registration number:

ITMCTR2025001157

最近更新日期:

Date of Last Refreshed on:

2025-06-12

注册时间:

Date of Registration:

2025-06-12

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于“脾为之卫”理论探讨气交灸干预轻中度溃疡性结肠炎患者的临床疗效研究

Public title:

Exploring the Clinical Efficacy of Qi Jiao Jiao Intervention in Mild to Moderate Ulcerative Colitis Patients Based on the Theory of "Spleen as the Guard"

注册题目简写:

气交灸干预轻中度溃疡性结肠炎的临床疗效研究

English Acronym:

Clinical efficacy of Qi Jiao Jiao intervention in mild to moderate ulcerative colitis

研究课题的正式科学名称:

基于“脾为之卫”理论探讨气交灸干预轻中度溃疡性结肠炎患者的临床疗效研究

Scientific title:

Exploring the Clinical Efficacy of Qi Jiao Jiao Intervention in Mild to Moderate Ulcerative Colitis Patients Based on the Theory of "Spleen as the Guard"

研究课题的正式科学名称简写:

“脾为之卫” 指导下气交灸干预 UC 的 随机对照 研究

Scientific title acronym:

A randomized controlled study on the intervention of Qi Jiao Jiao in UC under the guidance of "Spleen as the Guard"

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

Y24076 ;

申请注册联系人:

李旻

研究负责人:

李旻

Applicant:

Li Min

Study leader:

Li Min

申请注册联系人电话:

Applicant telephone:

13851708402

研究负责人电话:

Study leader's telephone:

13851708402

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

852744862@qq.com

研究负责人电子邮件:

Study leader's E-mail:

852744862@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市秦淮区汉中路155号江苏省中医院南院东16病区

研究负责人通讯地址:

江苏省南京市秦淮区汉中路155号江苏省中医院南院东16病区

Applicant address:

No.155 Hanzhong Road Qinhuai District Nanjing City Jiangsu Province China

Study leader's address:

No.155 Hanzhong Road Qinhuai District Nanjing City Jiangsu Province China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省中医院

Applicant's institution:

Jiangsu Province Hospital of TCM

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025NL-055-02

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

南京中医药大学附属医院(江苏省中医院)伦理委员会

Name of the ethic committee:

Ethics Committee of Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

伦理委员会批准日期:

Date of approved by ethic committee:

2025/2/27 0:00:00

伦理委员会联系人:

王卯

Contact Name of the ethic committee:

Wang Mao

伦理委员会联系地址:

江苏省南京市秦淮区汉中路155号江苏省中医院

Contact Address of the ethic committee:

No. 155 Hanzhong Road Qinhuai District Nanjing City Jiangsu Province China

伦理委员会联系人电话:

Contact phone of the ethic committee:

025-86560515

伦理委员会联系人邮箱:

Contact email of the ethic committee:

545255223@qq.com

研究实施负责(组长)单位:

江苏省中医院

Primary sponsor:

Jiangsu Province Hospital of TCM

研究实施负责(组长)单位地址:

江苏省南京市秦淮区汉中路155号

Primary sponsor's address:

No. 155 Hanzhong Road Qinhuai District Nanjing City Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu Province

City:

Nanjing City

单位(医院):

江苏省中医院

具体地址:

江苏省南京市秦淮区汉中路155号

Institution
hospital:

Jiangsu Province Hospital of TCM

Address:

No. 155 Hanzhong Road Qinhuai District Nanjing City Jiangsu Province

经费或物资来源:

江苏省中医院

Source(s) of funding:

Jiangsu Province Hospital of TCM

研究疾病:

溃疡性结肠炎

研究疾病代码:

Target disease:

ulcerative colitis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

(1)主要疗效指标:溃疡性结肠炎中医症状体征分级量化积分、部分 Mayo 评分、实验室指标(血液 TNF-α、IL-6) (2)次要疗效指标:炎症性肠病生活质量(IBDQ)评分)

Objectives of Study:

Main objective: To verify the clinical efficacy and immune indicators of Qi Jiao Jiao in patients with mild to moderate ulcerative colitis; Secondary objective: To explore the effect of Qi moxibustion on the quality of life of patients with mild to moderate ulcerative colitis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 符合诊断标准,确诊为轻中度溃疡性结肠炎的患者 2.年龄在 18-75 周岁,包括 18 岁和 75 岁 3. 自愿接受本研究并签署知情同意书者,获得知情同意书过程应符合 GCP 规定

Inclusion criteria

1. Patients who meet the diagnostic criteria and are diagnosed with mild to moderate ulcerative colitis 2. Age between 18-75 years old including 18 and 75 years old 3. Those who voluntarily accept this study and sign the informed consent form should comply with GCP regulations during the process of obtaining informed consent

排除标准:

1. 合并严重并发症 2. 有严重精神障碍、沟通障碍无法配合者 3. 妊娠期或哺乳期的患者 4.对艾叶过敏患者 5. 神阙穴周围皮肤有破溃、炎症或瘢痕组织

Exclusion criteria:

1. Merge serious complications 2. Individuals with severe mental and communication disorders who are unable to cooperate 3. Pregnant or lactating patients 4. For patients allergic to mugwort leaves 5. The skin around the Shenque acupoint has ulceration inflammation or scar tissue

研究实施时间:

Study execute time:

From 2025-01-01

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-05-01

To      2026-03-31

干预措施:

Interventions:

组别:

对照组

样本量:

40

Group:

control group

Sample size:

干预措施:

按照江苏省中医院优势病种中医护理方案溃疡性结肠炎(久痢)提供常规护理

干预措施代码:

Intervention:

Provide routine care for ulcerative colitis (chronic dysentery) according to the Traditional Chinese Medicine nursing plan for advantageous diseases of Jiangsu Provincial Hospital of Traditional Chinese Medicine

Intervention code:

组别:

干预组

样本量:

40

Group:

intervention group

Sample size:

干预措施:

在对照组的基础上加用气交灸,选取神阙穴,每天灸 1 次,每次连续灸 3-5 壮,约 15-20 分钟,连续灸 6 天,隔 1 天继续施灸,8 周为 1 个疗程

干预措施代码:

Intervention:

On the basis of the control group, Qi Jiao moxibustion was added, and Shenque acupoint was selected. Moxibustion was performed once a day for 3-5 consecutive minutes each time, for about 15-20 minutes. Moxibustion was continued for 6 consecutive days, and moxibustion was continued every other day. One course of treatment was 8 weeks

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu Province

City:

Nanjing City

单位(医院):

江苏省中医院

单位级别:

三级甲等

Institution/hospital:

Jiangsu Province Hospital of TCM

Level of the institution:

Grade III Grade A

测量指标:

Outcomes:

指标中文名:

部分 Mayo 评分

指标类型:

主要指标

Outcome:

Partial Mayo Scoring Points

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

UC 中医症状体征分级量化积分

指标类型:

主要指标

Outcome:

UC Traditional Chinese Medicine Symptoms and Signs Grading Quantitative Integral

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由课题组数据收集成员按照随机信封法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Generate random sequences using the random envelope method by data collection members of the research group

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/index.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above